CollabRx Partners with Medical News Site to Launch Molecular Oncology Mobile App

By Uduak Grace Thomas Last week, CollabRx announced that it is collaborating with MedPage Today, the medical news arm of digital health and wellness firm Everyday Health, to develop a mobile application that will provide information about molecular testing and therapy development first to oncologists and pathologists and eventually patients. According to the company, the app, […]

CollabRx Launches Variant Interpretation Service With Initial Focus on Oncology

By Uduak Grace Thomas CollabRx this week launched its Genetic Variant Annotation, or GVA, service, which will provide variant interpretation services to the molecular diagnostics segment of the clinical laboratory market including hospital labs, research institutions, and academic medical centers. According to the company, its service pairs the results of genetic sequencing tests from institutions […]

Newly Public CollabRx Sees ‘Explosive Growth Potential’ for Informatics-based MDx Offering

By Uduak Grace Thomas CollabRx officials see “explosive growth potential” for the company’s target market of informatically guided genomic medicine, according to comments made during the firm’s first earnings call as a publicly traded company. CollabRx, which offers cloud-based interpretation of cancer genomics data, entered the public market last July when it was acquired by Tegal, a […]

Life Technologies, CollabRx forge molecular Dx data deal

Life Tech, CollabRx Ink Deal to Elucidate MDx Information

Colon Cancer Genome Analysis Reveals New Targets

Work appearing in the July 19th issue of Nature reports a comprehensive genomic analysis of colon and rectal cancer, combining data from 276 tumor samples. Involving more than 150 researchers at dozens of institutions, the analysis found new markers for aggressive tumors, along with uncovering an important role for the regulator gene MYC. The team also […]

Lung Cancer Molecular Disease Model Published in PLoS ONE

A team including leading lung cancer researchers, and CollabRx scientists, has just published a novel Lung Cancer Molecular Disease Model in PLoS ONE, a leading peer-reviewed open source journal. (